MVD

Across TCGA pan-cancer cohorts, MVD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MVD data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MVD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MVD expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where MVD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.628	0.375	.005	19	view →
HNSC	DFS	Tertile	II,III,IV	0.991	0.860	.012	13	view →
LUAD	DFS	Quartile	All	0.401	0.758	.011	6	view →
GBM	OS	Tertile	All	0.890	0.781	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MVD–PDAC (OS)

Open the PDAC breakdown →